Meeting Complex Challenges in Proteinuric Glomerular Disease: An Expert Review of Emerging Data and Novel Therapeutics for IgA Nephropathy

This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.

• Examine the undergirding pathophysiologic processes driving pathogenesis and progression of glomerular disease, emphasizing the critical importance of proteinuria as a clinical hallmark and clinical trial endpoint.
• Distinguish focal segmental IgA nephropathy (IgAN) from other forms of glomerular disease, from diagnosis to clinicopathology to evidence-based treatment.
• Describe the expanding clinical trial evidentiary base for novel therapies being investigated for IgAN, including current expert consensus guideline recommendations.
• Discuss the evolving regulatory landscape for novel therapies in IgAN, with expert insights into how these updates will directly impact clinical practice and improve patient care.
• Using a real-world, patient case-based approach, evaluate evidence-supported strategies for IgAN patient evaluation, disease diagnosis, and adaptive, longitudinal management using novel therapeutics.

Supported through an independent educational grant from Travere.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:
Jai Radhakrishnan, MD–has disclosed that he receives salary/employment from Columbia University. He receives grants from Goldfinch Bio and Vertex and has previously received a grant from Travere. He is also an advisor or consultant to ANI Pharmaceuticals, Inc, Aurinia Pharmaceuticals Inc., Angion Biomedica Corp, Equillium, Genzyme, GlaxoSmithKline, Mallinckrodt, Sanofi, and Travere.

Faculty:
Richard Lafayette, MD–has disclosed that he receives research support from Alexion, Calliditas, Chinook, Omeros, Otsuka, Roche, and Travere. He is also an advisor or consultant for Alexion, Aurinia, Calliditas, Chinook, Novartis, Omeros, Otsuka, Roche, and Travere.

Peer Reviewer:
Elizabeth Hendren, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.